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ABSTRACT
Preclinical models suggest that histone deacetylase (HDAC) and mammalian 
target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We 
designed a phase I study to determine the safety, maximum tolerated dose (MTD), 
recommended phase II dose (RP2D), and dose-limiting toxicities (DLTs) of combined 
mTOR inhibitor sirolimus (1 mg-5 mg PO daily) and HDAC inhibitor vorinostat (100 
mg-400 mg PO daily) in patients with advanced cancer. Seventy patients were 
enrolled and 46 (66%) were evaluable for DLT assessment since they completed 
cycle 1 without dose modification unless they had DLT. DLTs comprised grade 
4 thrombocytopenia (n = 6) and grade 3 mucositis (n = 1). Sirolimus 4 mg and 
vorinostat 300 mg was declared RP2D because MTD with sirolimus 5 mg caused 
significant thrombocytopenia. The grade 3 and 4 drug-related toxic effects (including 
DLTs) were thrombocytopenia (31%), neutropenia (8%), anemia (7%), fatigue (3%), 
mucositis (1%), diarrhea (1%), and hyperglycemia (1%). Of the 70 patients, 35 
(50%) required dose interruption or modification and 61 were evaluable for response. 
Partial responses were observed in refractory Hodgkin lymphoma (-78%) and 
perivascular epithelioid tumor (-54%), and stable disease in hepatocellular carcinoma 
and fibromyxoid sarcoma. In conclusion, the combination of sirolimus and vorinostat 
was feasible, with thrombocytopenia as the main DLT. Preliminary anticancer activity 
was observed in patients with refractory Hodgkin lymphoma, perivascular epithelioid 
tumor, and hepatocellular carcinoma.
Clinical Research Paper
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INTRODUCTION
Phosphoinositide 3-kinase (PI3K)/Akt signaling is 
an important cell survival pathway [1]. Activation of the 
PI3K/Akt pathway is associated with uncontrolled cell 
proliferation and resistance to apoptosis [2]. Mammalian 
target of rapamycin (mTOR) is phosphorylated in response 
to PI3K/Akt activation. The PI3K/Akt/mTOR pathway 
is constitutively activated in many different human 
cancers, including ovarian, breast, and colon cancers and 
glioblastoma [3-5]. Several mTOR complex 1 (mTORC1) 
inhibitors are used in the clinic for the treatment of various 
cancers [6-8].
Sirolimus is an allosteric mTORC1 inhibitor that 
has immunosuppressive [9] and antitumor properties [10, 
11]. It inhibits S6K and 4EBP1 phosphorylation, which 
decreases the translation of mRNAs that are critical for 
cell cycle progression, such as cyclin D1, and thus leads to 
cell cycle arrest and apoptosis [12]. In addition, sirolimus 
reduces the transcription of hypoxia-inducible factor 
(HIF1α) and subsequently leads to decreased production 
of vascular endothelial growth factor, demonstrating 
antiangiogenic effects in preclinical cancer models [13]. 
A paradoxical increase in p-AKT through disruption 
of a p70S6K-dependent negative feedback loop has been 
suggested as a mechanism of resistance to mTORC1 
inhibition [14]. Developing targeting strategies that can 
abrogate p-Akt upregulation in response to mTORC1 
inhibition is thus a putatively desirable approach for 
overcoming resistance to this family of drugs. 
Post-translational modifications of chromatin 
histones are key regulators of gene expression [15]. These 
modifications include acetylation and deacetylation of 
lysines in the tails of the core histones controlled by the 
balanced action of histone deacetylases (HDACs) and 
histone acetyltransferases [16]. HDACs also target non-
histone proteins, such as p53, tubulin, and transcription 
factors, and regulate cell proliferation, cell migration, 
and cell death. Aberrant expression of HDACs has been 
associated with diverse leukemias, lymphomas, and solid 
tumors [17]. Hydroxamate HDAC inhibitors, such as 
vorinostat, function as pan-HDAC inhibitors, targeting 
both class I and class II (including class IIb) HDACs. 
HDAC inhibitors kill cells through diverse mechanisms, 
including induction of oxidative injury, upregulation of 
death receptors, disruption of the cell cycle checkpoint, 
induction of heat shock protein 90 acetylation (leading 
to increased degradation of p-Akt), upregulation of 
proapoptotic proteins, and interference with proteasome 
function [18-20]. 
Vorinostat also may lead to inhibition of PI3K 
activity, possibly secondary to the modulation of 
vorinostat-induced gene expression [21]. Vorinostat 
diminishes the kinase activity of PIK3 in vitro, both in 
mantle cell lymphoma Jeko1 cells and in PC3 prostate 
cancer cells [21]. The combination of vorinostat 
and temsirolimus, an analogous ester of sirolimus, 
dramatically suppressed survivin levels and produced 
greater tumor growth inhibition and apoptosis than did 
single-agent temsirolimus in vivo [22]. Another preclinical 
study showed that, while HDAC inhibition alone led to 
inhibition of LKB1 and AMP-activated protein kinase 
and thus increased mTOR activity, the combination of 
an HDAC inhibitor and an mTOR inhibitor resulted in 
synergistic tumor cell death in Hodgkin lymphoma cell 
lines [23]. These preclinical data provided a mechanistic 
rationale for further exploration of this approach in clinical 
trials.
We hypothesized that combining vorinostat and 
sirolimus would increase the sensitivity of cancer cells to 
these drugs by simultaneously inhibiting mTOR, AKT, and 
HDAC. Therefore, we designed this study to determine the 
safety, maximum tolerated dose (MTD) and recommended 
phase II dose (RP2D), and dose-limiting toxicities (DLTs) 
of the combination of the mTOR inhibitor sirolimus (1 
mg-5 mg PO daily, q 28 days) and the HDAC inhibitor 
vorinostat (100 mg-400 mg PO daily, q 28 days) in 
patients with advanced cancer.
RESULTS
Patient characteristics
From March 2010 to December 2012, a total of 99 
patients were screened. Of those, 82 met eligibility criteria, 
and 70 were started on treatment at the dose escalation 
phase (Figure 1). For the 12 patients who did not start 
treatment, the reasons included lack of insurance coverage 
(n = 4), clinical deterioration (n = 3), patient preference 
(n = 1), or unknown reasons (n = 4). The 70 patients’ 
demographic and clinical characteristics are shown in 
Table 1. There were 35 men and 35 women. Fifty-three 
(76%) patients were white, and the median age at study 
enrollment was 58 years (range, 16-79 years). Colorectal 
cancer, sarcoma, melanoma, and hepatocellular carcinoma 
comprised nearly half of the cases. The median number of 
treatment cycles on the protocol was 2 (range, < 1-20), and 
the median number of previous treatments was 4 (range, 
0-9). Fifty-seven patients discontinued therapy because of 
disease progression, 8 because of intolerance, and 5 for 
other reasons, including noncompliance and withdrawal 
of consent. 
Toxicity
All 70 patients were evaluated for toxicity, and 
46 patients (66%) were evaluable for DLTs (patients 
who either had a DLT or completed cycle 1 without 
dose interruption). Dose level 5A, 5 mg of sirolimus 
and 300 mg of vorinostat, was declared the MTD of this 
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Figure 1: The CONSORT flow diagram depicting patients’ identification, enrollment and treatment.
Figure 2: Waterfall plot depicts percentage change in target lesions in 70 patients with advanced cancer treated with 
sirolimus and vorinostat in the escalation phase. Patients who either experienced clinical progression prior to first restaging 
images or had at least 1 restaging imaging study were considered evaluable for response (n = 61). Nine patients discontinued therapy for 
toxicity prior to first restaging and were excluded from the response evaluation. Those who discontinued therapy because of clinical disease 
progression, prior to restaging scans, were included (depicted arbitrarily as +20% and shown with +). 
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combination on the basis of the DLTs; however, because 
of significant non-dose-limiting hematological toxicity, 
mainly prolonged or recurrent thrombocytopenia, 4 mg of 
sirolimus and 300 mg of vorinostat were established as 
RP2D for further investigation. Six patients experienced 
a DLT during the first cycle, including 5 with grade 4 
thrombocytopenia and 1 with grade 3 mucositis (Table 2). 
One patient with grade 4 thrombocytopenia was treated at 
dose level 0; however, this patient had a baseline platelet 
count of 63,000/µL. The other DLTs were observed at 
either dose level 5A (n = 1) or dose level 6 (n = 4). 
Thrombocytopenia was the most common toxicity 
(Table 3): 20 patients experienced grade 3 (n = 12) or 
grade 4 (n = 8) thrombocytopenia during the study period, 
including those who experienced thrombocytopenia as a 
DLT during the first cycle. Thirteen patients experienced 
recurrent grade 2 or higher thrombocytopenia beyond 
the first cycle; 2 of these patients experienced prolonged 
grade 3 thrombocytopenia that required further dose 
modification and interruption. Other grade 3 and grade 4 
toxicities included neutropenia (grade 3, n = 5; grade 4, n 
= 1), anemia (grade 3, n = 3; grade 4, n = 2), fatigue (grade 
Table 1: Demographic and clinical characteristics of patients with advanced cancer in a phase I study of sirolimus and 
vorinostat
Characteristic Result
Sex, N (%)  
Female 35 (50%)
Male 35 (50%)
Median age at study enrollment, years (range) 58 (16–79) 
Race, N (%)  
White 53 (76%)
Black 11 (16%)
Other 6 (9%)
Disease type, N (%)  
Colorectal cancer 11 (16%)
Sarcoma 9 (13%)
Melanoma 8 (11%)
Hepatocellular carcinoma 6 (9%)
Neuroendocrine carcinoma 5 (7%)
Non-small cell lung cancer 4 (6%)
Kidney cancer 3 (4%)
Thyroid cancer 3 (4%)
Appendiceal cancer 2 (3%)
Bladder cancer 2 (3%)
Endometrial cancer 2 (3%)
Hodgkin lymphoma 2 (3%)
Mesothelioma 2 (3%)
Ovarian cancer 2 (3%)
Pancreatic or ampullary carcinoma 2 (3%)
Salivary gland cancer 2 (3%)
Breast cancer 1 (1%)
Cervical cancer 1 (1%)
Gastric cancer 1 (1%)
Prostate cancer 1 (1%)
Carcinoma of unknown primary 1 (1%)
Number of treatment cycles, median (range) 2 (<1–20)
Number of prior therapies, median (range) 4 (0–9)
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Figure 3: Representative restaging images of 2 patients who had a favorable response to therapy. A. Patient with refractory 
relapsed Hodgkin lymphoma at baseline and after 6 cycles of treatment at dose level 5A. The best response by Cheson criteria was a partial 
response (-78% tumor size compared to baseline). He remained on treatment for 20 cycles. B. Patient with a perivascular epithelioid tumor 
at baseline and after 6 cycles of treatment at dose level 6. The best response by RECIST 1.1 was a partial response (-54% tumor size 
compared to baseline). He remained on treatment for 8 cycles.
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3, n = 2), diarrhea (grade 3, n = 1), and hyperglycemia 
(grade 3, n = 1). One patient had recurrent grade 4 anemia 
beyond the first cycle, and another had recurrent grade 4 
neutropenia during the study. Thirty-five (50%) patients 
required dose interruptions and/or reduction. Of the 35, 
6 patients had dose interruption due to DLT during the 
first cycle, 14 patients had other toxicity-related dose 
interruption during the DLT period, and 15 patients had 
dose interruptions after the first cycle (DLT window) was 
completed. Eight (11%) patients discontinued the study 
drugs because of intolerance (hematological toxicity, n = 
4; nausea/vomiting or indigestion, n = 2; infection, n = 1, 
and renal insufficiency, n = 1).
Efficacy
Of the 70 treated patients, 14 experienced clinical 
progression before the first restaging scans and 47 
underwent at least 1 restaging imaging procedure during 
treatment on the protocol, and thus 61 were considered 
evaluable for response. Four patients had a partial 
response (PR, n = 2) or durable stable disease for more 
than 12 months (SD>12months, n = 2), as shown in 
Figure 2. The objective response rate was 3%, 2 patients 
experiencing a PR during the escalation phase. One patient 
with relapsed, refractory Hodgkin lymphoma, who had 
had 8 lines of previous therapy, including an autologous 
stem cell transplant, experienced a 78% reduction in 
target tumor lesions per Cheson criteria after 6 cycles of 
therapy and remained on the protocol for 20 cycles (18.7 
months), at which point he developed progressive disease. 
This patient was treated at dose level 5A. Another patient 
with perivascular epithelioid tumor, who was treated 
at dose level 6, had a gradual reduction by as much as 
54% in sum of target lesions after 6 cycles of therapy 
and stayed on treatment for 8 cycles. One patient with 
hepatocellular carcinoma and 1 patient with fibromyxoid 
sarcoma had SD>12months. Representative imaging 
studies for these patients are shown in Figure 3. At the 
time of analysis, 57 (81%) patients had discontinued 
therapy because of disease progression. Other reasons 
for study discontinuation included toxicity (n = 8 [11%]), 
withdrawal of consent without reported study-related 
Table 3: All grade 3 or grade 4 toxicities reported in a phase I study of sirolimus and vorinostat in patients with 
advanced cancer 
Toxicity G N (%)
Thrombocytopenia 3 12 (17%)
 4 8 (11%)
Neutropenia 3 5 (7%)
 4 1 (1%)
Anemia 3 3 (4%)
 4 2 (3%)
Fatigue 3 2 (3%)
Diarrhea 3 1 (1%)
Hyperglycemia 3 1 (1%)
Mucositis 3 1 (1%)
G, grade.
Table 2: Dose levels and DLTs in a phase I study of sirolimus and vorinostat in patients with advanced cancer
Dose
level
Sirolimus (orally, mg 
daily)
Vorinostat (orally, 
mg daily)
Number of patients 
treated
Number of patients 
experiencing DLT
0 1 100 10 1 (G4 thrombocytopenia)
1 2 100 11 0
2 2 200 9 0
3 3 200 8 0
4 3 300 8 0
5 4 300 9 0
5A 5 300 6 1 (G4 thrombocytopenia)
6 4 400 9 4 (G4 thrombocytopenia, n=3; G3 mucositis, n=1)
DLT, dose-limiting toxic effect; G, grade.
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toxicities (n = 3 [4%]), and noncompliance (n = 2 [3%]). 
The median duration of follow-up was 27.3 weeks (range, 
2.9-188 weeks). The median PFS was 9 weeks (95% CI: 
8-10.3 weeks). At the time of analysis, 63 (90%) patients 
had died. The median OS was 24.3 weeks (95% CI: 19.1-
31 weeks). 
Pharmacokinetics
Sirolimus levels were determined for 5 patients. 
Three of these patients were treated at dose level 5A 
(MTD), 1 at dose level 3, and 1 at dose level 6. Sirolimus 
levels during therapy ranged between 3.2 ng/mL and 33.5 
ng/mL, with a mean of 20.5 ng/mL, which was above the 
therapeutic range recommended for post-transplantation 
immunosuppression in these patients. Among those who 
had sirolimus levels drawn, 2 patients had SD>12 months 
and 1 patient had a PR. All patients experienced grade 3 
thrombocytopenia. Although the number of patients is 
small, no significant relationship between sirolimus level 
and degree of toxicity was observed on the basis of these 
patients’ samples. 
Molecular profiles
Among the 70 patients treated, 48 had molecular 
testing of their tumor, and 41 of them were evaluable for 
disease response assessment (Supplementary Table 1); 
however, only 10 patients had comprehensive targeted 
next-generation sequencing for molecular alterations of at 
least 45 or more genes. Among the 4 patients who had PR 
or SD>12 months, 1 patient with Hodgkin lymphoma had 
TSC2 loss, a molecular aberration that putatively activates 
the mTOR pathway. The molecular aberrations in patients 
who experienced a PR or SD>12 months are shown in 
Table 4. Complete list of detected molecular aberrations 
and treatment outcomes is in Supplementary table 1. 
DISCUSSION
Our study demonstrated that the combination of 4 
mg of sirolimus and 300 mg of vorinostat was feasible in 
patients with advanced malignancy. The DLTs included 
thrombocytopenia (5/6, 83%) and mucositis (1/6, 17%). 
Thrombocytopenia was the most frequent grade 3 or grade 
4 treatment-related toxicity (28.5%). This is not surprising 
since both single-agent sirolimus and single-agent 
vorinostat can cause thrombocytopenia. For instance, 
sirolimus was associated with thrombocytopenia in up to 
30% of patients who received higher doses (5 mg daily) 
after transplantation and in 10% of patients with advanced 
cancer [11, 24, 25]. Vorinostat was associated with grade 3 
or grade 4 thrombocytopenia in 5%-20% of cases [26-29].
A similar combination of everolimus, an mTOR 
inhibitor, and panobinostat, a pan-HDAC inhibitor, 
was evaluated in a phase I clinical trial in patients with 
lymphoma, including Hodgkin lymphoma [30]. Patients 
enrolled in this study had similar toxicity profiles to those 
in our study, with a high incidence of thrombocytopenia 
(59%) and neutropenia (up to 50%) at the effective 
dose level. The DLT was grade 4 thrombocytopenia. 
Neutropenia was not as common in our study, which may 
be explained by the different patient populations: unlike 
some patients in the other study, many of the patients in 
the current dose-escalation study had a solid tumor, with 
no history of heavy bone marrow-suppressive therapy. 
The incidence of pneumonia was also higher with the 
panobinostat and everolimus combination; we did not 
observe this in our study with sirolimus and vorinostat. 
In the current study, the 2 patients with 
Hodgkin lymphoma and 4 of the 6 patients with 
hepatocellular carcinoma experienced grade 3 or grade 
4 thrombocytopenia during treatment. On the basis 
of our observations, we speculate that the patients 
who had undergone prior myelotoxic chemotherapy 
or had a decreased liver function reserve had more 
severe thrombocytopenia. It is notable that the degree 
of thrombocytopenia was often not cumulative, and 
many patients who experienced grade 3 or grade 4 
thrombocytopenia had a spontaneous recovery, which even 
allowed dose reescalation of study drugs. Considering 
that the population included in our study had undergone 
multiple cancer treatments prior to study participation 
and that the inclusion criteria allowed baseline platelet 
counts of 50,000/µL, we believe that the severity of 
thrombocytopenia observed in this study was reasonably 
safe. 
Table 4: Molecular aberrations observed in patients who derived clinical benefit from the combination of sirolimus 
and vorinostat in a phase I study
Patient Disease Molecular aberration Best response
1 Perivascular epithelioid tumor KIT M541L* PR
2 Hodgkin lymphoma TSC2 loss XPO1 E571K PR
3 Fibromyxoid sarcoma APC A2122_C2123insA SD>12 months
4 Hepatocellular carcinoma KIT M541L* SD>12 months
PR, partial response; SD, stable disease.
*Possible germline polymorphism. 
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One patient in our study experienced grade 3 
mucositis, which was more likely related to sirolimus 
than to vorinostat. Another 4 patients experienced grade 
1 mucositis. This frequency was lower than expected 
considering that 60% of patients in the panobinostat and 
everolimus study had grade 1 to grade 2 mucositis during 
treatment [30]. We observed very few metabolic adverse 
events, such as hypertriglyceridemia or hyperglycemia, 
which are often associated with mTOR inhibitors. One 
patient did experience grade 3 hyperglycemia; this 
patient had had type II diabetes for more than 5 years 
prior to starting treatment on this protocol, along with 
other metabolic risk factors, including morbid obesity, 
hypertension, and hyperlipidemia. 
We did not observe any strong correlation between 
molecular aberrations related to PI3K/Akt/mTOR 
pathway activation and response to therapy, although the 
generalizability of this observation may be limited because 
of the small number of patients. Two patients were found 
to have activating PIK3CA mutations. One patient had 
bladder cancer with PIK3CA H1047L and was treated at 
dose level 4; however, he discontinued therapy because 
of worsening renal function (> grade 3) and was not 
evaluable for response. Another patient had hepatocellular 
carcinoma with PIK3CA H1047R and was treated at 
dose level 6. He had SD, with a 15% decrease in tumor 
measurements after the second cycle, but the disease had 
progressed rapidly at the next restaging. Only 1 of the 4 
patients who had a PR or SD>12 months had a molecular 
aberration related to the PI3K/Akt/mTOR pathway, a 
TSC2 loss. Inactivation of TSC2 leads to activation of 
mTOR; thus, it can be a target for mTOR inhibitor therapy. 
Preclinical and anecdotal evidence suggests that the loss 
of TSC2 signal may predict a better response to mTOR 
inhibitor therapy [31, 32]. One patient with a PR and one 
patient with a SD> 12 months had KIT M541L mutation; 
however, previous data suggested that this might be a 
common germline polymorphism rather than a driver 
mutation [33]. 
The most remarkable response was seen in a 
patient with heavily pretreated Hodgkin lymphoma, 
which is consistent with the results of in vitro preclinical 
experiments [23]. There is in vitro evidence of the 
immunomodulatory effects of HDAC inhibitors, including 
suppression of T cell PD-1 expression [34], upregulation 
of PD-1 ligands [35], and inhibition of regulatory T 
cells, which have the potential to enhance the antitumor 
immune response [36]. In addition, inhibition of the 
PI3K/Akt/mTOR pathway has been shown to selectively 
reduce the activity of regulatory T cells [37]. Even 
though mTOR inhibitors in general are deemed to have 
immunosuppressive properties, we believe that in the 
context of this study the combination of HDAC and mTOR 
inhibition can in fact activate an anticancer immune 
response through its effects on the microenvironment as 
well as its direct inhibitory effect on cancer cells. Clinical 
response to immunotherapy with a checkpoint inhibitor 
has been remarkable in patients with Hodgkin lymphoma 
[38]. It is plausible that patients with tumor types that 
exhibit a higher degree of immune dysregulation and 
an inflammatory microenvironment, such as Hodgkin 
lymphoma and hepatocellular carcinoma, experienced a 
more significant benefit from this combination because of 
the potential immunomodulatory role of this combination. 
Finally, about half of the patients required dose 
interruptions or dose reduction, which could plausibly 
alter the efficacy. However, our sample size was limited to 
demonstrate any dose-response relationship. 
This study has several limitations. First, 24 (34%) of 
the 70 patients were not available for DLT assessment, as 
protocol-defined DLT assessment required completion of 
the first cycle without dose reduction for any reason other 
than DLT. Some of these patients experienced clinical 
progression prior to completing the first cycle, and some 
had toxic effects that were significant enough to interrupt 
the doses but did not last long enough to meet the criteria 
for DLT. This may have resulted in underestimation of 
the toxic effects and thus identification of the RP2D at the 
lower dose level than the MTD. Second, both sirolimus 
and vorinostat are relatively infrequently used in the clinic 
because of the emergence of newer agents. Although our 
study findings suggest that combining mTOR and HDAC 
inhibitors can be meaningful, it might be challenging to 
find adequate support for further development because 
of the short residual patent life (if any) of both drugs in 
this combination. Nevertheless, the cost of this therapy is 
anticipated to decrease, which might be viewed favorably 
by cooperative groups or other non-commercial sources 
of funding. Furthermore, the protocol included correlative 
studies, but they were optional; at the time of analysis 
we did not have enough data to identify biomarkers 
of response. Finally, while most patients tolerated the 
treatment relatively well, some experienced dose-limiting 
or even dose-prohibitive thrombocytopenia. 
In summary, combining mTORC1 inhibition with 
HDAC inhibition appears to be a safe and efficacious 
strategy for several cancer types. On the basis of the 
activity signals observed in this study, we are currently 
enrolling patients with Hodgkin and non-Hodgkin 
lymphoma, hepatocellular carcinoma, or perivascular 
epithelioid tumor into expansion cohorts.
MATERIALS AND METHODS
This study was a non-randomized, open-label, 
dose-escalation phase I clinical trial of sirolimus and 
vorinostat (NCT01087554) performed at The University 
of Texas MD Anderson Cancer Center (MD Anderson). 
The primary objective was to determine the safety, MTD 
and RP2D, and DLTs of the combination of sirolimus and 
vorinostat in patients with advanced cancer. The protocol 
was approved by the Institutional Review Board. All 
Oncotarget67529www.impactjournals.com/oncotarget
participants gave informed consent prior to entering the 
study. 
We enrolled patients with histologically confirmed 
metastatic or locally advanced cancer who were treated at 
the Clinical Center for Targeted Therapy at MD Anderson 
between March 2010 and December 2012. Among those 
who presented to the Clinical Center for Targeted Therapy, 
patients who met all the eligibility criteria were selected. 
All patients had disease that had failed to respond to 
standard therapy, had progressed despite standard therapy, 
or for which there was no available therapy that would 
prolong survival by at least 3 months. Patients were 
required to be off systemic therapy for at least 3 weeks 
before starting the protocol (or 5 half-lives in the case 
of biologics or targeted agents). Other inclusion criteria 
included an Eastern Cooperative Oncology Group 
performance status of 0, 1, 2, or 3; adequate organ 
and bone marrow function, as defined by an absolute 
neutrophil count of 1,000/µL or greater, a platelet count of 
50,000/µL or greater, a total bilirubin level less than twice 
the institutional upper limits of normal (in the absence of 
Gilbert syndrome), an alanine aminotransferase level less 
than 2.5 times (less than 5 times for patients with liver 
involvement) the institutional upper limits of normal, 
and a creatinine level of 2.0 mg/dL or less; and the use 
of contraception during the study period. Patients were 
excluded if they had a history of myocardial infarction 
within 3 months prior to starting treatment, were pregnant 
or breastfeeding, or had undergone a major surgical 
procedure within 28 days before starting therapy. Palliative 
radiation therapy was allowed during the study treatment. 
The use of other standard or investigational anticancer 
agents was not allowed. 
Patients were enrolled at 8 dose levels. The starting 
doses were 1 mg of oral sirolimus daily and 100 mg of 
oral vorinostat daily for 28 days, and doses were increased 
according to a standard “3+3” dose escalation design 
(Table 2). The study allowed to enroll up to 3 additional 
patients to each dose level to further evaluate safety. The 
concomitant use of CYP3A4 inhibitors was discouraged. 
Dose modification was allowed for treatment-related toxic 
effects. Patients continued treatment until they experienced 
disease progression or intolerable toxic effects or until 
the treating physician or patient felt that it was not in the 
patient’s best interest to continue for any reason. 
Patients who had DLT or completed cycle 1 without 
dose modification were evaluable for the DLT analysis. 
Patients not evaluable for DLT were replaced. The MTD 
was defined as the highest dose at which no more than 
33% of patients developed a DLT. DLTs were treatment-
related grade 3 or grade 4 non-hematologic toxic effects, 
as defined by the U.S. National Cancer Institute’s Common 
Terminology Criteria for Adverse Events v 3.0, or as grade 
4 hematologic toxic effects lasting more than 7 days or 
accompanied by fever (for neutropenia) or bleeding (for 
thrombocytopenia) during cycle 1. Grade 3 toxicities such 
as hyperglycemia, nausea, vomiting, diarrhea, rash, and 
asymptomatic lipase elevation were excluded from the 
DLTs if manageable with appropriate medication. Serum 
sirolimus levels were measured when available to assess 
pharmacokinetics. Vorinostat levels were not assessed. 
Tumor genomic analyses were performed whenever 
feasible using PCR or next-generation sequencing-based 
methods such FoundationOne or FoundationOne Heme 
(Foundation Medicine, Boston, MA), IonTorrent (Life 
Technologies, Carlsbad, CA), MassARRAY (Sequenom, 
San Diego, CA) and PCR-based DNA sequencing method 
that used primers designed by MD Anderson’s Molecular 
Diagnostic Laboratory. 
Response to therapy was assessed according 
to the Response Evaluation Criteria in Solid Tumors 
(RECIST) 1.1 [39] or Revised Response Criteria for 
Malignant Lymphoma (Cheson criteria) [40]. The median 
progression-free survival (PFS) and overall survival (OS) 
were calculated using the Kaplan-Meier method.
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